Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Employees - 55, CEO - Harry Simeonidis, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -8.47, Piotroski Score(max is 10): 4, Working Capital: $5138618, Total Assets: $14862792, Retained Earnings: $-71056373, EBIT: -11579451, Total Liabilities: $6111476, Revenue: $3913257

- Current Price $ - Analyst Target Price $